• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LRRK2 与特发性帕金森病。

LRRK2 and idiopathic Parkinson's disease.

机构信息

Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Molecular Pharmacology Graduate Program, University of Pittsburgh, Pittsburgh, PA, USA.

出版信息

Trends Neurosci. 2022 Mar;45(3):224-236. doi: 10.1016/j.tins.2021.12.002. Epub 2022 Jan 4.

DOI:10.1016/j.tins.2021.12.002
PMID:34991886
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8854345/
Abstract

The etiology of idiopathic Parkinson's disease (iPD) is multifactorial, and both genetics and environmental exposures are risk factors. While mutations in leucine-rich repeat kinase-2 (LRRK2) that are associated with increased kinase activity are the most common cause of autosomal dominant PD, the role of LRRK2 in iPD, independent of mutations, remains uncertain. In this review, we discuss how the architecture of LRRK2 influences kinase activation and how enhanced LRRK2 substrate phosphorylation might contribute to pathogenesis. We describe how oxidative stress and endolysosomal dysfunction, both of which occur in iPD, can activate non-mutated LRRK2 to a similar degree as pathogenic mutations. Similarly, environmental toxicants that are linked epidemiologically to iPD risk can also activate LRRK2. In aggregate, current evidence suggests an important role for LRRK2 in iPD.

摘要

特发性帕金森病(iPD)的病因是多因素的,遗传和环境暴露都是危险因素。虽然富含亮氨酸重复激酶 2(LRRK2)的突变与激酶活性的增加有关,是常染色体显性 PD 的最常见原因,但 LRRK2 在 iPD 中的作用,独立于突变,仍然不确定。在这篇综述中,我们讨论了 LRRK2 的结构如何影响激酶的激活,以及增强的 LRRK2 底物磷酸化如何有助于发病机制。我们描述了氧化应激和内溶酶体功能障碍,这两者都发生在 iPD 中,如何能以类似于致病性突变的程度激活非突变的 LRRK2。同样,流行病学上与 iPD 风险相关的环境毒物也可以激活 LRRK2。总的来说,目前的证据表明 LRRK2 在 iPD 中起着重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234a/8854345/5943e6c98434/nihms-1765014-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234a/8854345/14b807bc8db8/nihms-1765014-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234a/8854345/ca6618b83bea/nihms-1765014-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234a/8854345/d4a77a23d744/nihms-1765014-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234a/8854345/5943e6c98434/nihms-1765014-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234a/8854345/14b807bc8db8/nihms-1765014-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234a/8854345/ca6618b83bea/nihms-1765014-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234a/8854345/d4a77a23d744/nihms-1765014-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/234a/8854345/5943e6c98434/nihms-1765014-f0004.jpg

相似文献

1
LRRK2 and idiopathic Parkinson's disease.LRRK2 与特发性帕金森病。
Trends Neurosci. 2022 Mar;45(3):224-236. doi: 10.1016/j.tins.2021.12.002. Epub 2022 Jan 4.
2
LRRK2 activation in idiopathic Parkinson's disease.LRRK2 在特发性帕金森病中的激活。
Sci Transl Med. 2018 Jul 25;10(451). doi: 10.1126/scitranslmed.aar5429.
3
LRRK2 and the Endolysosomal System in Parkinson's Disease.LRRK2 与帕金森病中的内溶酶体系统。
J Parkinsons Dis. 2020;10(4):1271-1291. doi: 10.3233/JPD-202138.
4
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.LRRK2、GBA 及其在自噬调节中的相互作用:对帕金森病治疗的影响。
Transl Neurodegener. 2022 Jan 31;11(1):5. doi: 10.1186/s40035-022-00281-6.
5
Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease.阐明富含亮氨酸重复蛋白激酶-2 在正常细胞和帕金森病中的功能的进展。
Curr Opin Cell Biol. 2020 Apr;63:102-113. doi: 10.1016/j.ceb.2020.01.001. Epub 2020 Feb 7.
6
The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.LRRK2 亮氨酸丰富重复激酶 2 的 G2019S 变异通过损害 GTPase RAB8A 的功能改变内溶酶体运输。
J Biol Chem. 2019 Mar 29;294(13):4738-4758. doi: 10.1074/jbc.RA118.005008. Epub 2019 Feb 1.
7
The LRRK2-macroautophagy axis and its relevance to Parkinson's disease.富含亮氨酸重复激酶2-巨自噬轴及其与帕金森病的相关性。
Biochem Soc Trans. 2017 Feb 8;45(1):155-162. doi: 10.1042/BST20160265.
8
LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants.LRRK2 激酶抑制可预防帕金森病相关环境毒物。
Neurobiol Dis. 2024 Jun 15;196:106522. doi: 10.1016/j.nbd.2024.106522. Epub 2024 May 3.
9
LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease.LRRK2 抑制可预防人类帕金森病中所见的内溶酶体缺陷。
Neurobiol Dis. 2020 Feb;134:104626. doi: 10.1016/j.nbd.2019.104626. Epub 2019 Oct 13.
10
Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.LRRK2 的家族性敲入突变导致溶酶体功能障碍和神经元内内源性不溶性 α-突触核蛋白的积累。
Neurobiol Dis. 2018 Mar;111:26-35. doi: 10.1016/j.nbd.2017.12.005. Epub 2017 Dec 12.

引用本文的文献

1
Role of Microglial Dysfunction in Parkinson's Disease: From Multifactorial Causes to Neurodegeneration.小胶质细胞功能障碍在帕金森病中的作用:从多因素病因到神经退行性变
Neurosci Bull. 2025 Sep 19. doi: 10.1007/s12264-025-01505-1.
2
LRRK2 kinase activity restricts NRF2-dependent mitochondrial protection in microglia.LRRK2激酶活性限制小胶质细胞中NRF2依赖的线粒体保护作用。
J Immunol. 2025 Sep 4. doi: 10.1093/jimmun/vkaf215.
3
Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.

本文引用的文献

1
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts.来自不同帕金森病队列的临床样本中LRRK2激活和Rab GTPase磷酸化的不同特征。
NPJ Parkinsons Dis. 2022 Jun 8;8(1):73. doi: 10.1038/s41531-022-00336-5.
2
Preventing Parkinson's Disease: An Environmental Agenda.预防帕金森病:环境议程。
J Parkinsons Dis. 2022;12(1):45-68. doi: 10.3233/JPD-212922.
3
Impact of Type II LRRK2 inhibitors on signaling and mitophagy.LRRK2 型抑制剂对信号转导和线粒体自噬的影响。
重新审视帕金森病的定义和分类:来自两个新兴生物学框架的见解。
J Neural Transm (Vienna). 2025 Sep 4. doi: 10.1007/s00702-025-03013-y.
4
Beyond interferons: Non-canonical roles of MITA/STING.超越干扰素:MITA/STING的非经典作用
Cell Insight. 2025 Jul 24;4(5):100266. doi: 10.1016/j.cellin.2025.100266. eCollection 2025 Oct.
5
Derailed degradation: LRRK2-dependent exocytosis in Parkinson's disease.脱轨的降解:帕金森病中依赖LRRK2的胞吐作用。
Proc Natl Acad Sci U S A. 2025 Aug 12;122(32):e2515758122. doi: 10.1073/pnas.2515758122. Epub 2025 Aug 4.
6
Generation of Leucine-Rich Repeat Kinase 2 (LRRK2) Knockout Neuroblastoma Cells SH-SY5Y by CRISPR/Cas9-Mediated Genome Editing.通过CRISPR/Cas9介导的基因组编辑生成富含亮氨酸重复激酶2(LRRK2)基因敲除的神经母细胞瘤细胞SH-SY5Y
Biochem Genet. 2025 Jul 2. doi: 10.1007/s10528-025-11174-4.
7
Induced Pluripotent Stem Cells Derived Cellular Models for Investigating Parkinson's Disease Pathogenesis and Drug Screening.用于研究帕金森病发病机制和药物筛选的诱导多能干细胞衍生细胞模型
Stem Cell Rev Rep. 2025 Oct;21(7):1883-1900. doi: 10.1007/s12015-025-10931-7. Epub 2025 Jun 30.
8
LRRK2-mediated mitochondrial dysfunction in Parkinson's disease.帕金森病中由LRRK2介导的线粒体功能障碍
Biochem J. 2025 May 28;482(11):BCJ20253062. doi: 10.1042/BCJ20253062.
9
Leucine-rich repeat kinase 2 biomarkers for Parkinson's disease.帕金森病的富含亮氨酸重复激酶2生物标志物。
Biochem J. 2025 May 28;482(11):BCJ20253099. doi: 10.1042/BCJ20253099.
10
Protective Effect of the LRRK2 Kinase Inhibition in Human Fibroblasts Bearing the Genetic Variant GBA1 K198E: Implications for Parkinson's Disease.LRRK2激酶抑制对携带遗传变异GBA1 K198E的人成纤维细胞的保护作用:对帕金森病的意义。
Neuromolecular Med. 2025 May 21;27(1):42. doi: 10.1007/s12017-025-08864-y.
Biochem J. 2021 Oct 15;478(19):3555-3573. doi: 10.1042/BCJ20210375.
4
LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells.LRRK2 激酶抑制剂可恢复神经元细胞氧化应激诱导的细胞衰老。
Oxid Med Cell Longev. 2021 Jul 8;2021:9969842. doi: 10.1155/2021/9969842. eCollection 2021.
5
Parkinson's Disease Genetics and Pathophysiology.帕金森病遗传学与病理生理学。
Annu Rev Neurosci. 2021 Jul 8;44:87-108. doi: 10.1146/annurev-neuro-100720-034518.
6
Structural analysis of the full-length human LRRK2.全长人 LRRK2 的结构分析。
Cell. 2021 Jun 24;184(13):3519-3527.e10. doi: 10.1016/j.cell.2021.05.004. Epub 2021 Jun 8.
7
Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2.激酶结构域的构象和动力学驱动 LRRK2 的亚细胞定位和激活。
Proc Natl Acad Sci U S A. 2021 Jun 8;118(23). doi: 10.1073/pnas.2100844118.
8
ArfGAP1 inhibits mTORC1 lysosomal localization and activation.ArfGAP1 抑制 mTORC1 溶酶体定位和激活。
EMBO J. 2021 Jun 15;40(12):e106412. doi: 10.15252/embj.2020106412. Epub 2021 May 14.
9
Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.帕金森病相关激酶 LRRK2 的慢性抑制的临床前模型研究揭示了内溶酶体系统在体内功能的改变。
Mol Neurodegener. 2021 Mar 19;16(1):17. doi: 10.1186/s13024-021-00441-8.
10
The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.工业溶剂三氯乙烯诱导帕金森病大鼠模型中 LRRK2 激酶活性和多巴胺能神经元退行性变。
Neurobiol Dis. 2021 Jun;153:105312. doi: 10.1016/j.nbd.2021.105312. Epub 2021 Feb 23.